Co‑processed excipients are key functional materials for oral solid dosage forms. Unlike conventionally physically blended pre‑mixed excipients, they undergo special co‑processing technologies to reconstruct the microscopic powder structure, which markedly improves powder flowability, compressibility and disintegration performance. They greatly simplify the direct‑compression formulation process and shorten formulation R&D cycles, making them a vital option for the development of modified‑release preparations and innovative drugs. For a long time, the domestic high‑end co‑processed excipient market has been heavily reliant on imports, with supply‑chain risks, high costs and registration‑document constraints restricting the development of pharmaceutical formulation enterprises.
It will continuously optimize the processes of existing products, improve batch‑to‑batch consistency and scale up large‑scale production capacity; enhance domestic and overseas registration qualifications to consolidate the foundation for global supply; strengthen technical service capabilities and establish in‑depth collaboration with formulation developers to address practical formulation pain points faced by pharmaceutical enterprises. Beyond standardized co‑processed excipient products, we also offer custom development services for pharmaceutical companies at home and abroad. Tailored proprietary co‑processed excipients can be developed according to customers’ API characteristics, formulation processes, performance indicators and registration requirements. We provide one‑stop collaborative development support covering formula development, process exploration, lab‑scale and pilot trials, as well as GMP‑compliant large‑scale production, to accommodate diverse R&D demands for generic drugs, modified new drugs and innovative drugs.
Co‑processed excipients are key functional materials for oral solid dosage forms. Unlike conventionally physically blended pre‑mixed excipients, they undergo special co‑processing technologies to reconstruct the microscopic powder structure, which markedly improves powder flowability, compressibility and disintegration performance. They greatly simplify the direct‑compression formulation process and shorten formulation R&D cycles, making them a vital option for the development of modified‑release preparations and innovative drugs. For a long time, the domestic high‑end co‑processed excipient market has been heavily reliant on imports, with supply‑chain risks, high costs and registration‑document constraints restricting the development of pharmaceutical formulation enterprises.
It will continuously optimize the processes of existing products, improve batch‑to‑batch consistency and scale up large‑scale production capacity; enhance domestic and overseas registration qualifications to consolidate the foundation for global supply; strengthen technical service capabilities and establish in‑depth collaboration with formulation developers to address practical formulation pain points faced by pharmaceutical enterprises. Beyond standardized co‑processed excipient products, we also offer custom development services for pharmaceutical companies at home and abroad. Tailored proprietary co‑processed excipients can be developed according to customers’ API characteristics, formulation processes, performance indicators and registration requirements. We provide one‑stop collaborative development support covering formula development, process exploration, lab‑scale and pilot trials, as well as GMP‑compliant large‑scale production, to accommodate diverse R&D demands for generic drugs, modified new drugs and innovative drugs.
